Comparison of inflammatory biomarkers for detection of coronary stenosis in patients with stable coronary artery disease

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 1, 2013, Pages 112-118

  Uydu, H A ^a   Bostan, M ^a   Yilmaz, A ^a   Demir, A ^a   Atak, M ^a   Satiroglu, O ^a   Temiz, A ^a   Cicek, Y ^a   Erdogan, T ^a   Cetin, M ^a   Canga, A ^a  

^a RECEP TAYYIP ERDOGAN UNIVERSITY   (Turkey)

Author keywords

Atherosclerosis; Coronary artery disease; hsCRP; Lp PLA2; MPO

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C REACTIVE PROTEIN; MYELOPEROXIDASE; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PEROXIDASE;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; BLOOD; MIDDLE AGED; VERY ELDERLY;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; CORONARY STENOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PEROXIDASE;

MLCS; MLOWN;

EID: 84878577271     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. LIBBY P, RIDKER PM, MASERI A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
2. WILSON PW, D'AGOSTINO RB, LEVY D, BELANGER AM, S ILBERSHATZ H, KANNEL WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847.
3. CASLAKE MJ, PACKARD CJ. Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease. Curr Opin Lipidol 2003; 14: 347-352.
4. CURRIE CJ, POOLE CD, CONWAY P. Evaluation of the association between the first observation and the longitudinal change in C-reactive protein, and allcause mortality. Heart 2008; 94: 457-462.
5. BALDUS S, HEESCHEN C, MEINERTZ T, ZEIHER AM, EISERICH JP, MÜNZEL T, SIMOONS ML, HAMM CW; CAPTURE INVESTIGATORS. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003; 108: 1440-1445.
6. DADA N, KIM NW, WOLFERT RL. Lp-PLA2: an emerging biomarker of coronary heart disease. Expert Rev Mol Diagn 2002; 2: 17-22.
7. LIBBY P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365-372.
8. LANMAN RB, WOLFERT RL, FLEMING JK, JAFFE AS, ROBERTS WL, WARNICK GR, MCCONNELL JP. Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults. Prev Cardiol 2006; 9: 138-143.
9. PACKARD CJ, O'REILLY DS, CASLAKE MJ, MCMAHON AD, FORD I, COONEY J, MACPHEE CH, SUCKLING KE, KRISHNA M, WILKINSON FE, RUMLEY A, LOWE GD. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000; 343: 1148-1155.
10. CORSETTI JP, RAINWATER DL, MOSS AJ, ZAREBA W, SPARKS CE. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients. Clin Chem 2006; 52: 1331-1338.
11. BLAKE GJ, DADA N, FOX JC, MANSON JE, RIDKER PM. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 2001; 38: 1302-1306.
12. BRILAKIS ES, MCCONNELL JP, LENNON RJ, ELESBER AA, MEYER JG, BERGER PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at followup. Eur Heart J 2005; 26: 137-144.
13. LAGRAND WK, VISSER CA, HERMENS WT, NIESSEN HW, VERHEUGT FW, WOLBINK GJ, HACK CE. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 1999; 100: 96-102.
14. CAVUSOGLU E, RUWENDE C, ENG C, CHOPRA V, YANAMADALA S, CLARK LT, PINSKY DJ, MARMUR JD. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol 2007: 99; 1364-1368.
15. DÜZGÜNÇINAR O, YAVUZ B, HAZIROLAN T, DENIZ A, TOKGÓZO LU SL, AKATA D, DEMIRPENÇE E. Plasma myeloperoxidase is related to the severity of coronary artery disease. Acta Cardiol 2008; 63: 147-152.
16. WAINSTEIN RV, WAINSTEIN MV, RIBEIRO JP, DORNELLES LV, TOZZATI P, ASHTON-PROLLA P, EWALD IP, VIETTA G, POLANCZYK CA. Association between myeloperoxidase polymorphisms and its plasma levels with severity of coronary artery disease. Clin Biochem 2010; 43: 57-62.
17. KUBALA L, LU G, BALDUS S, BERGLUND L, EISERICH JP. Plasma levels of myeloperoxidase are not elevated in patients with stable coronary artery disease. Clin Chim Acta 2008; 394: 59-62.
18. ROMAN RM, WENDLAND AE, POLANCZYK CA. Myeloperoxidase and coronary arterial disease: from research to clinical practice. Arq Bras Cardiol 2008; 91: 11-19.
19. STEFANESCU A, BRAUN S, NDREPEPA G, KOPPARA T, PAVACI H, MEHILLI J, SCHÓMIG A, KASTRATI A. Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. Am Heart J 2008; 155: 356-360.